IntelGenx Files Non-Provisional U.S. Patent Application for Oil-Based Active Ingredients

April 16, 2019

SAINT LAURENT, Quebec, April 16, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has filed a new non-provisional patent application at the Unites States Patent and Trademark Office entitled “Lipophilic Active Oral Film Formulation And Method Of Making The Same.”

The patent application covers a newly-developed platform that enables the incorporation of oil-based (lipophilic) active ingredients into oral film formulations. This new platform, suitable for both VersaFilmTM and VetaFilmTM, is compatible with several of IntelGenx’ current projects including Montelukast, Loxapine and cannabis-infused films. The technology may also be used when more than one active ingredients, such as THC and CBD, are applied in a single film product.

“This new filing adds to the global intellectual property estate that we are building for VersaFilmTM and VetaFilmTM,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We anticipate that this application will also be filed in several other international jurisdictions as the application progresses in the United States.”  

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmTM and VetaFilmTM technology platforms.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for oral film technology platforms, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at

Forward Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at, and also filed with Canadian securities regulatory authorities at IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information please contact:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232


Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203

IGX Logo Medium Size.jpg

Source: IntelGenx Technologies Corp.